公开(公告)号：US20140221982A1

公开(公告)日：2014-08-07

申请号：US14014030

申请日：2013-08-29

申请人： Erik Gatenholm

发明人： Erik Gatenholm

IPC分类号： A61M37/00 ,  A61L31/04 ,  A61F2/02

CPC分类号： A61L27/38 ,  A61F2/022 ,  A61K9/009 ,  A61L27/3604 ,  A61L27/54 ,  A61L2300/64

摘要： A novel process for bacterial production of nanocellulose hydrogel pouches for applications for cell therapy, cell encapsulation, cell delivery, cell proliferation and cell differentiation has been invented. The process is based on fermentation of bacteria producing nanocellulose in oxygen permeable mold interconnected with tubing with diameter less than 5 mm. The resulting Bacterial Nanocellulose (BNC) hydrogel pouch is biocompatible and non-degradable in the human body. The inner wall of the pouch is highly porous and supports cell migration, cell proliferation and cell differentiation. The wall of the pouch allows controlled diffusion of extracellular components. The BNC pouch with injected cells can be implanted and used for treatment of diseases such as diabetes by local delivery of insulin. There are numerous applications of BNC pouches with injected cells in tissue engineering, regenerative medicine and cancer treatment.

摘要翻译： 已经发明了用于细胞治疗，细胞包封，细胞递送，细胞增殖和细胞分化的纳米纤维素水凝胶袋的细菌生产的新方法。 该过程基于在透氧模具中产生纳米纤维的细菌的发酵，其与直径小于5mm的管道相互连接。 所得的细菌纳米纤维素（BNC）水凝胶袋在人体内是生物相容的且不可降解的。 袋的内壁是高度多孔的，并且支持细胞迁移，细胞增殖和细胞分化。 袋的壁允许细胞外组分的受控扩散。 注射细胞的BNC袋可植入并用于通过局部输送胰岛素治疗糖尿病等疾病。 在组织工程，再生医学和癌症治疗中，注射细胞的BNC袋有许多应用。

公开(公告)号：US20240157629A1

公开(公告)日：2024-05-16

申请号：US18550279

申请日：2022-03-14

申请人： Hector Martinez ,  Patrick Thayer ,  Erik Gatenholm ,  Holger Eickhoff ,  Cellink Bioprinting AB

发明人： Hector Martinez ,  Patrick Thayer ,  Erik Gatenholm ,  Holger Eickhoff

IPC分类号： B29C64/106 ,  B29C64/182 ,  B29C64/209 ,  B33Y30/00 ,  B33Y40/20

CPC分类号： B29C64/106 ,  B29C64/182 ,  B29C64/209 ,  B33Y30/00 ,  B33Y40/20

摘要： Bioprinters use biological inks (i.e. bioinks) to produce biomaterials such as cell cultures (including 3D cell cultures), living tissues, and organs. Bioprinters as described by the present invention include those capable of performing high-throughput industrial scale assays, applications, and development while maintaining precision.

公开(公告)号：US20180326665A1

公开(公告)日：2018-11-15

申请号：US15755767

申请日：2016-08-31

申请人： Erik Gatenholm ,  Ivan Tournier ,  Paul Gatenholm ,  Cellink AB

发明人： Erik Gatenholm ,  Ivan Tournier ,  Paul Gatenholm

IPC分类号： B29C64/364 ,  C12M3/00 ,  B33Y30/00 ,  B29C64/264 ,  B29C64/245 ,  B33Y50/02 ,  B29C64/393 ,  B29C64/25

CPC分类号： B29C64/364 ,  B01L1/02 ,  B01L3/0241 ,  B01L2200/0636 ,  B01L2300/0681 ,  B29C64/245 ,  B29C64/25 ,  B29C64/264 ,  B29C64/393 ,  B29L2031/40 ,  B33Y30/00 ,  B33Y40/00 ,  B33Y50/02 ,  B33Y70/00 ,  B33Y80/00 ,  C12M21/08 ,  F24F3/161 ,  F24F13/28 ,  F24F2011/0004

摘要： Clean chamber technology for 3D printers and bioprinters is described. An airtight chamber or enclosure is provided so that positive pressure can be created inside the chamber. Unfiltered air is sucked in from outside into the chamber through a high efficiency filter such as a HEPA filter, using an electrically powered fan or blower, filtering out at least about 99% of particles and contaminants. The filtered air is then pushed into a 3D printing area inside the chamber and out through vents within the frame of the chamber. The technology provides a clean environment for 3D bioprinting of human tissue models and organs and 3D cell culturing without requiring clean room facilities.